Characteristics and clinical outcomes of HCTs with and without DLI
| Patient characteristics . | HCTs with DLI (n = 191) . | HCTs without DLI (n = 608) . | P . |
|---|---|---|---|
| Age at transplant (y) | .04 | ||
| Median (range) | 9.5 (0.2-25.2) | 10.5 (0.1-27.2) | |
| Sex | .74 | ||
| Female | 83 (43.5%) | 255 (41.9%) | |
| Race | .57 | ||
| White | 142 (74.3%) | 451 (74.2%) | |
| African ancestry | 35 (18.3%) | 99 (16.3%) | |
| Other | 14 (7.3%) | 58 (9.5%) | |
| Diagnosis | .05 | ||
| ALL | 51 (26.7%) | 187 (30.8%) | |
| AML | 82 (42.9%) | 215 (35.4%) | |
| Other leukemia | 19 (9.9%) | 58 (9.5%) | |
| Lymphoma | 3 (1.6%) | 37 (6.1%) | |
| Nonmalignant disorder | 36 (18.8%) | 111 (18.3%) | |
| Donor type | <.001 | ||
| MSD | 44 (23.0%) | 113 (18.6%) | |
| MUD | 53 (27.7%) | 264 (43.4%) | |
| HAPLO | 94 (49.2%) | 231 (38.0%) | |
| Transplant number | .76 | ||
| 1 | 151 (79.1%) | 472 (77.9%) | |
| >2 | 40 (20.9%) | 134 (22.1%) | |
| Transplant year | .05 | ||
| 2005-2009 | 43 (22.5%) | 193 (31.7%) | |
| 2010-2015 | 81 (42.4%) | 225 (37.0%) | |
| 2016-2021 | 67 (35.1%) | 190 (31.3%) | |
| aGVHD | |||
| Grade 1-4 aGVHD | 60 (31.4%) | 237 (39.0%) | .06 |
| Grade 2-4 aGVHD | 40 (21.1%) | 159 (26.4%) | .15 |
| cGVHD | 24 (12.6%) | 110 (18.1%) | .08 |
| Relapse | 56 (29.3%) | 122 (20.1%) | .01 |
| Death | 75 (39.3%) | 237 (39.0%) | .99 |
| Patient characteristics . | HCTs with DLI (n = 191) . | HCTs without DLI (n = 608) . | P . |
|---|---|---|---|
| Age at transplant (y) | .04 | ||
| Median (range) | 9.5 (0.2-25.2) | 10.5 (0.1-27.2) | |
| Sex | .74 | ||
| Female | 83 (43.5%) | 255 (41.9%) | |
| Race | .57 | ||
| White | 142 (74.3%) | 451 (74.2%) | |
| African ancestry | 35 (18.3%) | 99 (16.3%) | |
| Other | 14 (7.3%) | 58 (9.5%) | |
| Diagnosis | .05 | ||
| ALL | 51 (26.7%) | 187 (30.8%) | |
| AML | 82 (42.9%) | 215 (35.4%) | |
| Other leukemia | 19 (9.9%) | 58 (9.5%) | |
| Lymphoma | 3 (1.6%) | 37 (6.1%) | |
| Nonmalignant disorder | 36 (18.8%) | 111 (18.3%) | |
| Donor type | <.001 | ||
| MSD | 44 (23.0%) | 113 (18.6%) | |
| MUD | 53 (27.7%) | 264 (43.4%) | |
| HAPLO | 94 (49.2%) | 231 (38.0%) | |
| Transplant number | .76 | ||
| 1 | 151 (79.1%) | 472 (77.9%) | |
| >2 | 40 (20.9%) | 134 (22.1%) | |
| Transplant year | .05 | ||
| 2005-2009 | 43 (22.5%) | 193 (31.7%) | |
| 2010-2015 | 81 (42.4%) | 225 (37.0%) | |
| 2016-2021 | 67 (35.1%) | 190 (31.3%) | |
| aGVHD | |||
| Grade 1-4 aGVHD | 60 (31.4%) | 237 (39.0%) | .06 |
| Grade 2-4 aGVHD | 40 (21.1%) | 159 (26.4%) | .15 |
| cGVHD | 24 (12.6%) | 110 (18.1%) | .08 |
| Relapse | 56 (29.3%) | 122 (20.1%) | .01 |
| Death | 75 (39.3%) | 237 (39.0%) | .99 |
P values <.05 are in bold font.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia.